Y-mAbs Therapeutics, Inc. - Special Call Transcript
Greetings, and welcome to the Y-mAbs Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host for today's conference, Dr. Claus Møller. Thank you, Doctor. Please go ahead.
¸ -
Thank you very much. Good morning, everybody, and thanks for joining us today. I'm joined today by Y-mAbs Founder, Chairman and President, Thomas Gad; and our Chief Financial Officer, Bo Kruse. We are holding this call to provide an update of securing regulatory status for omburtamab. We completed the rolling submission for the BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in August this year. And late on Friday, October 2, we received refusal -- a refusal to file a letter from the FDA.
Upon its preliminary review, the FDA determined that certain parts of the CMC module and the clinical module of the BLA required further detail to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |